You can buy Lucicapiva at the lowest price at Nextgen.ooo online pharmacy. Capivasertib is a serine/threonine kinase inhibitor used to treat hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer. Hormone receptor-positive (HR), especially estrogen receptor-positive, HER2-negative breast cancer is the most common subtype of metastatic breast cancer, resulting in more than 400,000 deaths each year. Although endocrine therapy is the first line of treatment, resistance eventually occurs, leaving chemotherapy as the only, but often ineffective, remaining treatment. Therefore, significant research has been conducted to develop genetically targeted therapies. The PIK3/AKT pathway is one of the most frequently activated pathways in breast cancer, mainly through a constitutively active mutation in AKT1, a loss-of-function mutation in PTEN, a negative regulator of the PIK3/AKT pathway, or PIK3CA mutations. Therefore, targeting the PIK3/AKT pathway represents a promising approach to the treatment of breast cancer, which led to the development of capivasertib, a pan-AKT kinase inhibitor.
 
On November 17, 2023, capivasertib was approved by the FDA for the treatment of adult patients with HR-positive, HER2-negative locally advanced or metastatic breast cancer with one or more alterations in the PIK3CA/AKT1/PTEN genes in combination with fulvestrant. This approval is based on favorable results from the CAPItello-291 study, in which the combination of capivasertib and fulvestrant reduced the risk of disease progression or death by 50% compared with fulvestrant alone.